The Evaluation of COVID-19 Vaccination Rates, Side Effects and Perspectives of Rheumatic Patients, A Cross-sectional Study in a University-based Teaching Hospital, Thailand (Eng)
Article Sidebar
Main Article Content
Abstract
Objective
This study aims to investigate the vaccination rate among rheumatic patients, the incidence of COVID-19 infection in the vaccinated and unvaccinated groups, the post-vaccination side effects, and opinions regarding the decision whether to vaccinate against COVID-19 infection.
Methods
A cross-sectional study was conducted on rheumatic patients at the Department of Medicine, Naresuan University Hospital, Thailand. A questionnaire was developed for the survey.
Results
The total number of rheumatic patients was 384, and 363 individuals (94.5%) received the COVID-19 vaccine. Among those who received at least 2 doses, the COVID-19 infection rate was 44.69%. In the groups of patients who received either one dose or no vaccine, the COVID-19 infection rate was 57.69%. Eighty-three patients (22.86%) had adverse effects, predominantly fever and fatigue. Among those receiving vaccination, 71.34% decided to protect themselves from COVID-19 infection, while among those who decided not to get vaccinated, 85.71% opted out because of vaccine side effects. Regarding the relationship between factors leading rheumatic patients to receive the COVID-19 vaccine, no statistically significant factors were found (p-value < 0.05).
Conclusion
The majority of rheumatic patients received the COVID-19 vaccine. Patients who received the full dosage of the vaccine had a lower infection rate. Most side effects were mild. Patients mainly chose to vaccinate themselves for self-protection against infection, while others chose not to vaccinate due to concern about vaccine side effects. Furthermore, no factors correlated with COVID-19 vaccination among rheumatic patients.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
(ใส่ข้อความเดียวกันกับ ก๊อปปี้ไลน์ก็ได้)ดูตัวอย่างได้ที่หน้าบทความ---บทความนี้ตีพิมพ์เป็นลิขสิทธื์ของใคร...
References
Department of Disease Control, Ministry of Public Health. COVID-19 Vaccination Progress Report [Internet]. Nonthaburi: Ministry of Public Health; 2023 [cited 2026 Feb 14]. Available from: https://ddc.moph.go.th/vaccine-covid19/getFiles/9/1678949996284.pdf
Landewe RBM, Kroon FPB, Alunno A, et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Ann Rheum Dis. Dec 2022;81(12):1628-1639. doi:10.1136/annrheumdis-2021-222006
Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5. Arthritis & Rheumatology. 2023;75(1):E1-E16. doi:https://doi.org/10.1002/art.42372
Molteni E, Canas LS, Klaser K, et al. Post-vaccination infection rates and modification of COVID-19 symptoms in vaccinated UK school-aged children and adolescents: A prospective longitudinal cohort study. Lancet Reg Health Eur. Aug 2022;19:100429. doi:10.1016/j.lanepe.2022.100429
Iba T, Levy JH. Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination. Trends Cardiovasc Med. Jul 2022;32(5):249-256. doi:10.1016/j.tcm.2022.02.008
Guo Y, Cao XS, Yang HT, Zhou MG, Yu B. Global incidence pattern and factors associated with common cutaneous reactions related to COVID-19 vaccination of 2.55 million participants in real-world settings: A systematic review and meta-analysis. J Glob Health. Feb 10 2023;13:06008. doi:10.7189/jogh.13.06008
SeyedAlinaghi S, Karimi A, Pashaei Z, et al. Safety and Adverse Events Related to COVID-19 mRNA Vaccines; a Systematic Review. Arch Acad Emerg Med. 2022;10(1):e41. doi:10.22037/aaem.v10i1.1597
Yao R, Liang R, Lu J, et al. Impact of coronavirus disease 2019 on psoriatic arthritis: A multiregional observational study. Rheumatology & Autoimmunity. 2024; 4:226‐234. doi:10.1002/rai2.12134234
Alshukairi AN, Al-Omari A, Albeity A, et al. COVID-19 breakthrough infections in rheumatic diseases patients after vaccination. Journal of Infection and Public Health. 2022/06/01/ 2022;15(6):685-688. doi:https://doi.org/10.1016/j.jiph.2022.05.005
Peng D, Kelly A, Brady B, Faasse K, El-Haddad C, Frade S. Perspectives and experiences of COVID-19 vaccination in people with autoimmune and inflammatory rheumatic disease. Patient Education and Counseling. 2024/01/01/ 2024;118:107996. doi:https://doi.org/10.1016/j.pec.2023.107996
Tariq J, Gupta L. Safety and efficacy of COVID-19 vaccines in pregnant women with rheumatic diseases: an immunologic perspective. Rheumatol Int. Aug 2021;41(8):1545-1547. doi:10.1007/s00296-021-04918-z
Butt IN, van Eeden C, Burns KK, et al. COVID-19 Vaccination Perceptions in Patients With Rheumatic Disease: A Cross-Sectional Online Survey. J Rheumatol. May 2023;50(5):690-696. doi:10.3899/jrheum.220765
Shaw YP, Hustek S, Nguyen N, et al. Rheumatic disease patient decision-making about COVID-19 vaccination: a qualitative analysis. BMC Rheumatol. Nov 29 2022;6(1):76. doi:10.1186/s41927-022-00307-6
Safary A, Esalatmanesh K, Eftekharsadat AT, Jafari Nakjavani M-R, Khabbazi A. Autoimmune inflammatory rheumatic diseases post-COVID‐19 vaccination. International Immunopharmacology. 2022/09/01/ 2022;110:109061. doi:https://doi.org/10.1016/j.intimp.2022.109061
Wantha O, Mahakkanukrauh A, Tuydaung K, et al. Attitudes and factors affecting decision-making regarding COVID-19 vaccination among autoimmune rheumatic disease patients. International Journal of Rheumatic Diseases. 2023;26(4):751-758. doi:https://doi.org/10.1111/1756-185X.14644
Widhani A, Hasibuan AS, Rismawati R, et al. Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis. Vaccines. 2023;11(9). doi:10.3390/vaccines11091456
Assawasaksakul T, Lertussavavivat T, Sathitratanacheewin S, et al. Comparison of Immunogenicity and Safety of Inactivated, Adenovirus-Vectored, and Heterologous Adenovirus-Vectored/mRNA Vaccines in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Prospective Cohort Study. Vaccines (Basel). 2022; 26;10(6):853. doi: 10.3390/vaccines10060853.
Roseti L, Grigolo B. COVID-19 and rheumatic diseases: A mini-review. Front Med (Lausanne). 2022;9:997876. doi:10.3389/fmed.2022.997876
Fu XL, Qian Y, Jin XH, et al. COVID-19 in patients with systemic lupus erythematosus: A systematic review. Lupus. May 2022;31(6):684-696. doi:10.1177/09612033221093502
Department of Medical Services, Ministry of Public Health, Thailand. Clinical Practice Guideline for Diagnosis, Treatment, and Prevention of Coronavirus Disease 2019 (COVID-19) in Hospital Settings, 17 April 2021 [Internet]. Nonthaburi: Ministry of Public Health; 2021 [cited 2026 Feb 14]. Available from: https://covid19.dms.go.th/backend///Content//Content_File/Covid_Health/Attach/25640417114830AM_CPG_COVID-19%20_ns_%2017apr%202021.pdf
Narongtanupol P, Narongtanupol P. Immune response after receiving Covid-19 vaccination. Academic journal of community public health. 2022;8:178-194.
Palazzo L, Lindblom J, Kihlgren Olsson E, Nikiphorou E, Wincup C, Saha S, et al. Breakthrough SARS-CoV-2 infection in fully vaccinated patients with systemic lupus erythematosus: results from the COVID-19 Vaccination in Autoimmune Disease (COVAD) study. Rheumatol Int. 2024;44(10):1923-33. doi: 10.1007/s00296-024-05682-6.
Division of Epidemiology, Department of Disease Control, Ministry of Public Health, Thailand. Guidelines for the Implementation of Adult Immunization Programs, 2023 [Internet]. Nonthaburi: Department of Disease Control; 2023 [cited 2026 Feb 14]. Available from: https://ddc.moph.go.th/uploads/publish/1366120230209074448.pdf
